ID   TAF1_HUMAN              Reviewed;        1872 AA.
AC   P21675; A5CVC8; A5CVC9; A5CVD0; A5CVD1; B1Q2X3; Q59FZ3; Q6IUZ1;
AC   Q70Q86; Q70Q87; Q70T00; Q70T01; Q70T02; Q70T03;
DT   01-MAY-1991, integrated into UniProtKB/Swiss-Prot.
DT   01-MAY-1992, sequence version 2.
DT   10-MAY-2017, entry version 195.
DE   RecName: Full=Transcription initiation factor TFIID subunit 1;
DE            EC=2.3.1.48;
DE            EC=2.7.11.1;
DE   AltName: Full=Cell cycle gene 1 protein;
DE   AltName: Full=TBP-associated factor 250 kDa;
DE            Short=p250;
DE   AltName: Full=Transcription initiation factor TFIID 250 kDa subunit;
DE            Short=TAF(II)250;
DE            Short=TAFII-250;
DE            Short=TAFII250;
GN   Name=TAF1; Synonyms=BA2R, CCG1, CCGS, TAF2A;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, AND SUBCELLULAR
RP   LOCATION.
RC   TISSUE=Laryngeal carcinoma;
RX   PubMed=2038334; DOI=10.1128/MCB.11.6.3317;
RA   Sekiguchi T., Nohiro Y., Nakamura Y., Hisamoto N., Nishimoto T.;
RT   "The human CCG1 gene, essential for progression of the G1 phase,
RT   encodes a 210-kilodalton nuclear DNA-binding protein.";
RL   Mol. Cell. Biol. 11:3317-3325(1991).
RN   [2]
RP   PRELIMINARY NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=3169001;
RA   Sekiguchi T., Miyata T., Nishimoto T.;
RT   "Molecular cloning of the cDNA of human X chromosomal gene (CCG1)
RT   which complements the temperature-sensitive G1 mutants, tsBN462 and
RT   ts13, of the BHK cell line.";
RL   EMBO J. 7:1683-1687(1988).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND INTERACTION WITH TBP AND
RP   TAFS.
RX   PubMed=7680771; DOI=10.1038/362175a0;
RA   Ruppert S., Wang E.H., Tjian R.;
RT   "Cloning and expression of human TAFII250: a TBP-associated factor
RT   implicated in cell-cycle regulation.";
RL   Nature 362:175-179(1993).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM N-TAF1), AND INVOLVEMENT IN DYT3.
RC   TISSUE=Brain;
RX   PubMed=17273961; DOI=10.1086/512129;
RA   Makino S., Kaji R., Ando S., Tomizawa M., Yasuno K., Goto S.,
RA   Matsumoto S., Tabuena M.D., Maranon E., Dantes M., Lee L.V.,
RA   Ogasawara K., Tooyama I., Akatsu H., Nishimura M., Tamiya G.;
RT   "Reduced neuron-specific expression of the TAF1 gene is associated
RT   with X-linked dystonia-parkinsonism.";
RL   Am. J. Hum. Genet. 80:393-406(2007).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT VAL-269.
RG   NIEHS SNPs program;
RL   Submitted (MAY-2004) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15772651; DOI=10.1038/nature03440;
RA   Ross M.T., Grafham D.V., Coffey A.J., Scherer S., McLay K., Muzny D.,
RA   Platzer M., Howell G.R., Burrows C., Bird C.P., Frankish A.,
RA   Lovell F.L., Howe K.L., Ashurst J.L., Fulton R.S., Sudbrak R., Wen G.,
RA   Jones M.C., Hurles M.E., Andrews T.D., Scott C.E., Searle S.,
RA   Ramser J., Whittaker A., Deadman R., Carter N.P., Hunt S.E., Chen R.,
RA   Cree A., Gunaratne P., Havlak P., Hodgson A., Metzker M.L.,
RA   Richards S., Scott G., Steffen D., Sodergren E., Wheeler D.A.,
RA   Worley K.C., Ainscough R., Ambrose K.D., Ansari-Lari M.A., Aradhya S.,
RA   Ashwell R.I., Babbage A.K., Bagguley C.L., Ballabio A., Banerjee R.,
RA   Barker G.E., Barlow K.F., Barrett I.P., Bates K.N., Beare D.M.,
RA   Beasley H., Beasley O., Beck A., Bethel G., Blechschmidt K., Brady N.,
RA   Bray-Allen S., Bridgeman A.M., Brown A.J., Brown M.J., Bonnin D.,
RA   Bruford E.A., Buhay C., Burch P., Burford D., Burgess J., Burrill W.,
RA   Burton J., Bye J.M., Carder C., Carrel L., Chako J., Chapman J.C.,
RA   Chavez D., Chen E., Chen G., Chen Y., Chen Z., Chinault C.,
RA   Ciccodicola A., Clark S.Y., Clarke G., Clee C.M., Clegg S.,
RA   Clerc-Blankenburg K., Clifford K., Cobley V., Cole C.G., Conquer J.S.,
RA   Corby N., Connor R.E., David R., Davies J., Davis C., Davis J.,
RA   Delgado O., Deshazo D., Dhami P., Ding Y., Dinh H., Dodsworth S.,
RA   Draper H., Dugan-Rocha S., Dunham A., Dunn M., Durbin K.J., Dutta I.,
RA   Eades T., Ellwood M., Emery-Cohen A., Errington H., Evans K.L.,
RA   Faulkner L., Francis F., Frankland J., Fraser A.E., Galgoczy P.,
RA   Gilbert J., Gill R., Gloeckner G., Gregory S.G., Gribble S.,
RA   Griffiths C., Grocock R., Gu Y., Gwilliam R., Hamilton C., Hart E.A.,
RA   Hawes A., Heath P.D., Heitmann K., Hennig S., Hernandez J.,
RA   Hinzmann B., Ho S., Hoffs M., Howden P.J., Huckle E.J., Hume J.,
RA   Hunt P.J., Hunt A.R., Isherwood J., Jacob L., Johnson D., Jones S.,
RA   de Jong P.J., Joseph S.S., Keenan S., Kelly S., Kershaw J.K., Khan Z.,
RA   Kioschis P., Klages S., Knights A.J., Kosiura A., Kovar-Smith C.,
RA   Laird G.K., Langford C., Lawlor S., Leversha M., Lewis L., Liu W.,
RA   Lloyd C., Lloyd D.M., Loulseged H., Loveland J.E., Lovell J.D.,
RA   Lozado R., Lu J., Lyne R., Ma J., Maheshwari M., Matthews L.H.,
RA   McDowall J., McLaren S., McMurray A., Meidl P., Meitinger T.,
RA   Milne S., Miner G., Mistry S.L., Morgan M., Morris S., Mueller I.,
RA   Mullikin J.C., Nguyen N., Nordsiek G., Nyakatura G., O'dell C.N.,
RA   Okwuonu G., Palmer S., Pandian R., Parker D., Parrish J.,
RA   Pasternak S., Patel D., Pearce A.V., Pearson D.M., Pelan S.E.,
RA   Perez L., Porter K.M., Ramsey Y., Reichwald K., Rhodes S.,
RA   Ridler K.A., Schlessinger D., Schueler M.G., Sehra H.K.,
RA   Shaw-Smith C., Shen H., Sheridan E.M., Shownkeen R., Skuce C.D.,
RA   Smith M.L., Sotheran E.C., Steingruber H.E., Steward C.A., Storey R.,
RA   Swann R.M., Swarbreck D., Tabor P.E., Taudien S., Taylor T.,
RA   Teague B., Thomas K., Thorpe A., Timms K., Tracey A., Trevanion S.,
RA   Tromans A.C., d'Urso M., Verduzco D., Villasana D., Waldron L.,
RA   Wall M., Wang Q., Warren J., Warry G.L., Wei X., West A.,
RA   Whitehead S.L., Whiteley M.N., Wilkinson J.E., Willey D.L.,
RA   Williams G., Williams L., Williamson A., Williamson H., Wilming L.,
RA   Woodmansey R.L., Wray P.W., Yen J., Zhang J., Zhou J., Zoghbi H.,
RA   Zorilla S., Buck D., Reinhardt R., Poustka A., Rosenthal A.,
RA   Lehrach H., Meindl A., Minx P.J., Hillier L.W., Willard H.F.,
RA   Wilson R.K., Waterston R.H., Rice C.M., Vaudin M., Coulson A.,
RA   Nelson D.L., Weinstock G., Sulston J.E., Durbin R.M., Hubbard T.,
RA   Gibbs R.A., Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence of the human X chromosome.";
RL   Nature 434:325-337(2005).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 837-1872 (ISOFORM 4).
RC   TISSUE=Brain;
RA   Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S.,
RA   Ohara O., Nagase T., Kikuno R.F.;
RL   Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1347-1801 (ISOFORMS 2A; 2C AND 2D),
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1347-1592 (ISOFORM 2E), NUCLEOTIDE
RP   SEQUENCE [MRNA] OF 1498-1801 (ISOFORM 3), AND INVOLVEMENT IN DYT3.
RC   TISSUE=Fetal brain;
RX   PubMed=12928496; DOI=10.1073/pnas.1831949100;
RA   Nolte D., Niemann S., Muller U.;
RT   "Specific sequence changes in multiple transcript system DYT3 are
RT   associated with X-linked dystonia parkinsonism.";
RL   Proc. Natl. Acad. Sci. U.S.A. 100:10347-10352(2003).
RN   [9]
RP   SEQUENCE REVISION.
RA   Nolte D.;
RL   Submitted (MAY-2007) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1347-1801 (ISOFORMS 2E; 2G; 2H AND 2I),
RP   AND ALTERNATIVE SPLICING.
RX   PubMed=17952504; DOI=10.1007/s00335-007-9063-z;
RA   Herzfeld T., Nolte D., Muller U.;
RT   "Structural and functional analysis of the human TAF1/DYT3 multiple
RT   transcript system.";
RL   Mamm. Genome 18:787-795(2007).
RN   [11]
RP   FUNCTION.
RX   PubMed=8450888; DOI=10.1038/362179a0;
RA   Hisatake K., Hasegawa S., Takada R., Nakatani Y., Horikoshi M.,
RA   Roeder R.G.;
RT   "The p250 subunit of native TATA box-binding factor TFIID is the cell-
RT   cycle regulatory protein CCG1.";
RL   Nature 362:179-181(1993).
RN   [12]
RP   FUNCTION, PHOSPHORYLATION AT SER-137 AND SER-307, AND ATP-BINDING.
RX   PubMed=8625415; DOI=10.1016/S0092-8674(00)81055-7;
RA   Dikstein R., Ruppert S., Tjian R.;
RT   "TAFII250 is a bipartite protein kinase that phosphorylates the base
RT   transcription factor RAP74.";
RL   Cell 84:781-790(1996).
RN   [13]
RP   INTERACTION WITH SV40 LARGE T ANTIGEN.
RX   PubMed=8647434; DOI=10.1101/gad.10.11.1369;
RA   Damania B., Alwine J.C.;
RT   "TAF-like function of SV40 large T antigen.";
RL   Genes Dev. 10:1369-1381(1996).
RN   [14]
RP   INTERACTION WITH HERPES SIMPLEX VIRUS 1 ICP4.
RX   PubMed=8649420; DOI=10.1128/MCB.16.6.3085;
RA   Carrozza M.J., DeLuca N.A.;
RT   "Interaction of the viral activator protein ICP4 with TFIID through
RT   TAF250.";
RL   Mol. Cell. Biol. 16:3085-3093(1996).
RN   [15]
RP   FUNCTION, AND MUTAGENESIS.
RX   PubMed=9660973; DOI=10.1016/S1097-2765(00)80089-1;
RA   O'Brien T., Tjian R.;
RT   "Functional analysis of the human TAFII250 N-terminal kinase domain.";
RL   Mol. Cell 1:905-911(1998).
RN   [16]
RP   FUNCTION, INTERACTION WITH RB1, AND ATP-BINDING.
RX   PubMed=9858607; DOI=10.1128/MCB.19.1.846;
RA   Siegert J.L., Robbins P.D.;
RT   "Rb inhibits the intrinsic kinase activity of TATA-binding protein-
RT   associated factor TAFII250.";
RL   Mol. Cell. Biol. 19:846-854(1999).
RN   [17]
RP   INTERACTION WITH ASF1A.
RX   PubMed=10759893; DOI=10.1046/j.1365-2443.2000.00319.x;
RA   Munakata T., Adachi N., Yokoyama N., Kuzuhara T., Horikoshi M.;
RT   "A human homologue of yeast anti-silencing factor has histone
RT   chaperone activity.";
RL   Genes Cells 5:221-233(2000).
RN   [18]
RP   FUNCTION.
RX   PubMed=11278496; DOI=10.1074/jbc.M009385200;
RA   Solow S., Salunek M., Ryan R., Lieberman P.M.;
RT   "Taf(II) 250 phosphorylates human transcription factor IIA on serine
RT   residues important for TBP binding and transcription activity.";
RL   J. Biol. Chem. 276:15886-15892(2001).
RN   [19]
RP   INTERACTION WITH ASF1A.
RX   PubMed=12093919; DOI=10.1073/pnas.142627899;
RA   Chimura T., Kuzuhara T., Horikoshi M.;
RT   "Identification and characterization of CIA/ASF1 as an interactor of
RT   bromodomains associated with TFIID.";
RL   Proc. Natl. Acad. Sci. U.S.A. 99:9334-9339(2002).
RN   [20]
RP   INTERACTION WITH ASF1A AND ASF1B.
RX   PubMed=12842904; DOI=10.1074/jbc.M303549200;
RA   Umehara T., Horikoshi M.;
RT   "Transcription initiation factor IID-interactive histone chaperone
RT   CIA-II implicated in mammalian spermatogenesis.";
RL   J. Biol. Chem. 278:35660-35667(2003).
RN   [21]
RP   FUNCTION, AND INTERACTION WITH TP53.
RX   PubMed=15053879; DOI=10.1016/S1097-2765(04)00123-6;
RA   Li H.-H., Li A.G., Sheppard H.M., Liu X.;
RT   "Phosphorylation on Thr-55 by TAF1 mediates degradation of p53: a role
RT   for TAF1 in cell G1 progression.";
RL   Mol. Cell 13:867-878(2004).
RN   [22]
RP   IDENTIFICATION IN THE MLL1/MLL COMPLEX.
RX   PubMed=15960975; DOI=10.1016/j.cell.2005.04.031;
RA   Dou Y., Milne T.A., Tackett A.J., Smith E.R., Fukuda A., Wysocka J.,
RA   Allis C.D., Chait B.T., Hess J.L., Roeder R.G.;
RT   "Physical association and coordinate function of the H3 K4
RT   methyltransferase MLL1 and the H4 K16 acetyltransferase MOF.";
RL   Cell 121:873-885(2005).
RN   [23]
RP   HISTONE ACETYLTRANSFERASE ACTIVITY, AND MUTAGENESIS OF GLU-721 AND
RP   827-MET--ASP-829.
RX   PubMed=15870300; DOI=10.1128/MCB.25.10.4321-4332.2005;
RA   Hilton T.L., Li Y., Dunphy E.L., Wang E.H.;
RT   "TAF1 histone acetyltransferase activity in Sp1 activation of the
RT   cyclin D1 promoter.";
RL   Mol. Cell. Biol. 25:4321-4332(2005).
RN   [24]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [25]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1826, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [26]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1700 (ISOFORMS 2A AND
RP   4), PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1702 (ISOFORM 2G),
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1697 (ISOFORM 3), AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [27]
RP   ENZYME REGULATION.
RX   PubMed=22711989; DOI=10.1128/MCB.00416-12;
RA   Kloet S.L., Whiting J.L., Gafken P., Ranish J., Wang E.H.;
RT   "Phosphorylation-dependent regulation of cyclin D1 and cyclin A gene
RT   transcription by TFIID subunits TAF1 and TAF7.";
RL   Mol. Cell. Biol. 32:3358-3369(2012).
RN   [28]
RP   MISCELLANEOUS.
RX   PubMed=23184149; DOI=10.1093/hmg/dds499;
RA   Herzfeld T., Nolte D., Grznarova M., Hofmann A., Schultze J.L.,
RA   Muller U.;
RT   "X-linked dystonia parkinsonism syndrome (XDP, lubag): disease-
RT   specific sequence change DSC3 in TAF1/DYT3 affects genes in vesicular
RT   transport and dopamine metabolism.";
RL   Hum. Mol. Genet. 22:941-951(2013).
RN   [29]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-307, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [30]
RP   X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 1359-1638.
RX   PubMed=10827952; DOI=10.1126/science.288.5470.1422;
RA   Jacobson R.H., Ladurner A.G., King D.S., Tjian R.;
RT   "Structure and function of a human TAFII250 double bromodomain
RT   module.";
RL   Science 288:1422-1425(2000).
RN   [31]
RP   X-RAY CRYSTALLOGRAPHY (1.89 ANGSTROMS) OF 1501-1635, AND SUBUNIT.
RX   PubMed=22464331; DOI=10.1016/j.cell.2012.02.013;
RA   Filippakopoulos P., Picaud S., Mangos M., Keates T., Lambert J.P.,
RA   Barsyte-Lovejoy D., Felletar I., Volkmer R., Muller S., Pawson T.,
RA   Gingras A.C., Arrowsmith C.H., Knapp S.;
RT   "Histone recognition and large-scale structural analysis of the human
RT   bromodomain family.";
RL   Cell 149:214-231(2012).
RN   [32]
RP   X-RAY CRYSTALLOGRAPHY (2.30 ANGSTROMS) OF 579-1215 IN COMPLEX WITH
RP   TAF7, FUNCTION, AND INTERACTION WITH TAF7.
RX   PubMed=25412659; DOI=10.1038/cr.2014.148;
RA   Wang H., Curran E.C., Hinds T.R., Wang E.H., Zheng N.;
RT   "Crystal structure of a TAF1-TAF7 complex in human transcription
RT   factor IID reveals a promoter binding module.";
RL   Cell Res. 24:1433-1444(2014).
RN   [33]
RP   STRUCTURE BY ELECTRON MICROSCOPY (8.50 ANGSTROMS), AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=27007846; DOI=10.1038/nature17394;
RA   Louder R.K., He Y., Lopez-Blanco J.R., Fang J., Chacon P., Nogales E.;
RT   "Structure of promoter-bound TFIID and model of human pre-initiation
RT   complex assembly.";
RL   Nature 531:604-609(2016).
RN   [34]
RP   VARIANTS [LARGE SCALE ANALYSIS] VAL-269; GLY-297; ASP-453; LYS-651 AND
RP   ILE-691.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [35]
RP   INVOLVEMENT IN MRXS33, AND VARIANTS MRXS33 SER-575; ARG-786; HIS-955;
RP   TRP-1225; THR-1316; HIS-1431 AND HIS-1496.
RX   PubMed=26637982; DOI=10.1016/j.ajhg.2015.11.005;
RA   O'Rawe J.A., Wu Y., Doerfel M.J., Rope A.F., Au P.Y.,
RA   Parboosingh J.S., Moon S., Kousi M., Kosma K., Smith C.S., Tzetis M.,
RA   Schuette J.L., Hufnagel R.B., Prada C.E., Martinez F., Orellana C.,
RA   Crain J., Caro-Llopis A., Oltra S., Monfort S., Jimenez-Barron L.T.,
RA   Swensen J., Ellingwood S., Smith R., Fang H., Ospina S., Stegmann S.,
RA   Den Hollander N., Mittelman D., Highnam G., Robison R., Yang E.,
RA   Faivre L., Roubertie A., Riviere J.B., Monaghan K.G., Wang K.,
RA   Davis E.E., Katsanis N., Kalscheuer V.M., Wang E.H., Metcalfe K.,
RA   Kleefstra T., Innes A.M., Kitsiou-Tzeli S., Rosello M., Keegan C.E.,
RA   Lyon G.J.;
RT   "TAF1 Variants Are Associated with Dysmorphic Features, Intellectual
RT   Disability, and Neurological Manifestations.";
RL   Am. J. Hum. Genet. 97:922-932(2015).
RN   [36]
RP   VARIANTS ASP-472 AND CYS-1169.
RX   PubMed=25644381; DOI=10.1038/mp.2014.193;
RA   Hu H., Haas S.A., Chelly J., Van Esch H., Raynaud M., de Brouwer A.P.,
RA   Weinert S., Froyen G., Frints S.G., Laumonnier F., Zemojtel T.,
RA   Love M.I., Richard H., Emde A.K., Bienek M., Jensen C., Hambrock M.,
RA   Fischer U., Langnick C., Feldkamp M., Wissink-Lindhout W., Lebrun N.,
RA   Castelnau L., Rucci J., Montjean R., Dorseuil O., Billuart P.,
RA   Stuhlmann T., Shaw M., Corbett M.A., Gardner A., Willis-Owen S.,
RA   Tan C., Friend K.L., Belet S., van Roozendaal K.E.,
RA   Jimenez-Pocquet M., Moizard M.P., Ronce N., Sun R., O'Keeffe S.,
RA   Chenna R., van Boemmel A., Goeke J., Hackett A., Field M.,
RA   Christie L., Boyle J., Haan E., Nelson J., Turner G., Baynam G.,
RA   Gillessen-Kaesbach G., Mueller U., Steinberger D., Budny B.,
RA   Badura-Stronka M., Latos-Bielenska A., Ousager L.B., Wieacker P.,
RA   Rodriguez Criado G., Bondeson M.L., Anneren G., Dufke A., Cohen M.,
RA   Van Maldergem L., Vincent-Delorme C., Echenne B., Simon-Bouy B.,
RA   Kleefstra T., Willemsen M., Fryns J.P., Devriendt K., Ullmann R.,
RA   Vingron M., Wrogemann K., Wienker T.F., Tzschach A., van Bokhoven H.,
RA   Gecz J., Jentsch T.J., Chen W., Ropers H.H., Kalscheuer V.M.;
RT   "X-exome sequencing of 405 unresolved families identifies seven novel
RT   intellectual disability genes.";
RL   Mol. Psychiatry 21:133-148(2016).
CC   -!- FUNCTION: Largest component and core scaffold of the TFIID basal
CC       transcription factor complex (PubMed:25412659, PubMed:27007846).
CC       Contains novel N- and C-terminal Ser/Thr kinase domains which can
CC       autophosphorylate or transphosphorylate other transcription
CC       factors. Phosphorylates TP53 on 'Thr-55' which leads to MDM2-
CC       mediated degradation of TP53. Phosphorylates GTF2A1 and GTF2F1 on
CC       Ser residues. Possesses DNA-binding activity (PubMed:25412659).
CC       Essential for progression of the G1 phase of the cell cycle
CC       (PubMed:11278496, PubMed:15053879, PubMed:2038334, PubMed:8450888,
CC       PubMed:8625415, PubMed:9660973, PubMed:9858607). Exhibits histone
CC       acetyltransferase activity towards histones H3 and H4
CC       (PubMed:15870300). {ECO:0000269|PubMed:11278496,
CC       ECO:0000269|PubMed:15053879, ECO:0000269|PubMed:15870300,
CC       ECO:0000269|PubMed:2038334, ECO:0000269|PubMed:25412659,
CC       ECO:0000269|PubMed:27007846, ECO:0000269|PubMed:8450888,
CC       ECO:0000269|PubMed:8625415, ECO:0000269|PubMed:9660973,
CC       ECO:0000269|PubMed:9858607}.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC   -!- CATALYTIC ACTIVITY: Acetyl-CoA + [protein]-L-lysine = CoA +
CC       [protein]-N(6)-acetyl-L-lysine.
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC   -!- ENZYME REGULATION: Autophosphorylates on Ser residues. Inhibited
CC       by retinoblastoma tumor suppressor protein, RB1. Binding to TAF1
CC       or CIITA inhibits the histone acetyltransferase activity.
CC       {ECO:0000269|PubMed:22711989}.
CC   -!- SUBUNIT: TAF1 is the largest component of transcription factor
CC       TFIID that is composed of TBP and a variety of TBP-associated
CC       factors (PubMed:7680771). TAF1, when part of the TFIID complex,
CC       interacts with C-terminus of TP53 (PubMed:15053879). Part of a
CC       TFIID-containing RNA polymerase II pre-initiation complex that is
CC       composed of TBP and at least GTF2A1, GTF2A2, GTF2E1, GTF2E2,
CC       GTF2F1, GTF2H2, GTF2H3, GTF2H4, GTF2H5, GTF2B, TCEA1, ERCC2,
CC       ERCC3, TAF1, TAF2, TAF3, TAF4, TAF5, TAF6, TAF7, TAF8, TAF9,
CC       TAF10, TAF11, TAF12 and TAF13 (PubMed:27007846). Interacts with
CC       TAF7; the interaction is direct (PubMed:25412659). Component of
CC       some MLL1/MLL complex, at least composed of the core components
CC       KMT2A/MLL1, ASH2L, HCFC1/HCF1, WDR5 and RBBP5, as well as the
CC       facultative components BAP18, CHD8, E2F6, HSP70, INO80C, KANSL1,
CC       LAS1L, MAX, MCRS1, MGA, KAT8/MOF, PELP1, PHF20, PRP31, RING2,
CC       RUVB1/TIP49A, RUVB2/TIP49B, SENP3, TAF1, TAF4, TAF6, TAF7, TAF9
CC       and TEX10. RB1 interacts with the N-terminal domain of TAF1.
CC       Interacts with ASF1A and ASF1B (PubMed:10759893, PubMed:12093919,
CC       PubMed:12842904). Interacts (via bromo domains) with acetylated
CC       lysine residues on the N-terminus of histone H1.4, H2A, H2B, H3
CC       and H4 (in vitro). Interacts with SV40 Large T antigen
CC       (PubMed:8647434). Interacts with herpes simplex virus 1 ICP4
CC       (PubMed:8649420). {ECO:0000269|PubMed:10759893,
CC       ECO:0000269|PubMed:12093919, ECO:0000269|PubMed:12842904,
CC       ECO:0000269|PubMed:15053879, ECO:0000269|PubMed:15960975,
CC       ECO:0000269|PubMed:22464331, ECO:0000269|PubMed:25412659,
CC       ECO:0000269|PubMed:27007846, ECO:0000269|PubMed:7680771,
CC       ECO:0000269|PubMed:8647434, ECO:0000269|PubMed:8649420,
CC       ECO:0000269|PubMed:9858607}.
CC   -!- INTERACTION:
CC       P03255:- (xeno); NbExp=3; IntAct=EBI-491289, EBI-2603114;
CC       P35269:GTF2F1; NbExp=3; IntAct=EBI-491289, EBI-457886;
CC       P20226:TBP; NbExp=5; IntAct=EBI-491289, EBI-355371;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:2038334,
CC       ECO:0000269|PubMed:27007846}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=12;
CC         Comment=the TAF1/DYT3 multiple transcript system is composed of
CC         38 evolutionary conserved exons plus 5 downstream exons referred
CC         to as exons d1-d5 that are primate-specific. Multiple highly
CC         polymorphic variants can be generated by splicing exons d3 and
CC         d4 to various combinations of exons 1-37.;
CC       Name=1;
CC         IsoId=P21675-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P21675-2; Sequence=VSP_012362;
CC       Name=3;
CC         IsoId=P21675-3; Sequence=VSP_053382, VSP_053383, VSP_053384;
CC         Note=Contains a phosphoserine at position 1697.
CC         {ECO:0000244|PubMed:20068231};
CC       Name=4;
CC         IsoId=P21675-4; Sequence=VSP_053383;
CC         Note=Contains a phosphoserine at position 1700.
CC         {ECO:0000244|PubMed:20068231};
CC       Name=2a;
CC         IsoId=P21675-5; Sequence=VSP_053383, VSP_053384;
CC         Note=Contains a phosphoserine at position 1700.
CC         {ECO:0000244|PubMed:20068231};
CC       Name=2c;
CC         IsoId=P21675-6; Sequence=VSP_053384;
CC       Name=2d;
CC         IsoId=P21675-7; Sequence=VSP_053381, VSP_053384;
CC       Name=2e; Synonyms=2F;
CC         IsoId=P21675-8; Sequence=VSP_053379, VSP_053380;
CC       Name=2g;
CC         IsoId=P21675-9; Sequence=VSP_053381, VSP_053383, VSP_053384;
CC         Note=Contains a phosphoserine at position 1702.
CC         {ECO:0000244|PubMed:20068231};
CC       Name=2h;
CC         IsoId=P21675-10; Sequence=VSP_053375, VSP_053377;
CC       Name=2i;
CC         IsoId=P21675-11; Sequence=VSP_053376, VSP_053378;
CC       Name=N-TAF1; Synonyms=TA14-391;
CC         IsoId=P21675-12; Sequence=VSP_012362, VSP_053381;
CC         Note=Only detected in brain, highest expression in the caudate
CC         nucleus.;
CC   -!- PTM: Phosphorylated by casein kinase II in vitro.
CC       {ECO:0000269|PubMed:8625415}.
CC   -!- DISEASE: Dystonia 3, torsion, X-linked (DYT3) [MIM:314250]: A X-
CC       linked dystonia-parkinsonism disorder. Dystonia is defined by the
CC       presence of sustained involuntary muscle contractions, often
CC       leading to abnormal postures. DYT3 is characterized by severe
CC       progressive torsion dystonia followed by parkinsonism. It has a
CC       well-defined pathology of extensive neuronal loss and mosaic
CC       gliosis in the striatum (caudate nucleus and putamen) which
CC       appears to resemble that in Huntington disease.
CC       {ECO:0000269|PubMed:12928496, ECO:0000269|PubMed:17273961}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- DISEASE: Mental retardation, X-linked, syndromic, 33 (MRXS33)
CC       [MIM:300966]: A mental retardation syndrome characterized by
CC       intellectual deficit, delayed psychomotor development, delayed
CC       speech and language, and characteristic facial features. Mental
CC       retardation is defined by significantly below average general
CC       intellectual functioning associated with impairments in adaptive
CC       behavior and manifested during the developmental period.
CC       {ECO:0000269|PubMed:26637982}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- MISCELLANEOUS: Isoforms including the downstream (d) exons are
CC       preferentially expressed in brain, and may play a role in the
CC       regulation of genes involved in dopamine processing and transport.
CC   -!- SIMILARITY: Belongs to the TAF1 family. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/taf1/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; D90359; BAA14374.1; -; mRNA.
DR   EMBL; X07024; CAA30073.1; ALT_SEQ; mRNA.
DR   EMBL; AB300418; BAG15901.1; -; mRNA.
DR   EMBL; AY623109; AAT38105.1; -; Genomic_DNA.
DR   EMBL; AL590762; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL590763; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AB209316; BAD92553.1; -; mRNA.
DR   EMBL; AJ549247; CAD70490.1; -; mRNA.
DR   EMBL; AJ549248; CAD70491.3; -; mRNA.
DR   EMBL; AJ549249; CAD70492.2; -; mRNA.
DR   EMBL; AJ549250; CAD70493.3; -; mRNA.
DR   EMBL; AJ555148; CAD87527.2; -; mRNA.
DR   EMBL; AJ555149; CAD87528.2; -; mRNA.
DR   EMBL; AM711892; CAM98555.1; -; mRNA.
DR   EMBL; AM711893; CAM98556.1; -; mRNA.
DR   EMBL; AM711894; CAM98557.1; -; mRNA.
DR   EMBL; AM711895; CAM98558.1; -; mRNA.
DR   CCDS; CCDS14412.1; -. [P21675-2]
DR   CCDS; CCDS35325.1; -. [P21675-1]
DR   CCDS; CCDS69783.1; -. [P21675-12]
DR   PIR; A40262; A40262.
DR   RefSeq; NP_001273003.1; NM_001286074.1. [P21675-12]
DR   RefSeq; NP_004597.2; NM_004606.4. [P21675-2]
DR   RefSeq; NP_620278.1; NM_138923.3. [P21675-1]
DR   RefSeq; XP_005262354.1; XM_005262297.4. [P21675-4]
DR   UniGene; Hs.158560; -.
DR   PDB; 1EQF; X-ray; 2.10 A; A=1359-1638.
DR   PDB; 3AAD; X-ray; 3.30 A; A=1342-1629.
DR   PDB; 3UV4; X-ray; 1.89 A; A/B=1501-1635.
DR   PDB; 3UV5; X-ray; 2.03 A; A=1373-1635.
DR   PDB; 4RGW; X-ray; 2.30 A; A=579-1215.
DR   PDB; 4YYM; X-ray; 1.50 A; A/B=1497-1638.
DR   PDB; 4YYN; X-ray; 1.85 A; A/B=1497-1638.
DR   PDB; 5FUR; EM; 8.50 A; G=1-1872.
DR   PDB; 5I1Q; X-ray; 1.50 A; A=1497-1638.
DR   PDB; 5I29; X-ray; 1.21 A; A=1497-1638.
DR   PDBsum; 1EQF; -.
DR   PDBsum; 3AAD; -.
DR   PDBsum; 3UV4; -.
DR   PDBsum; 3UV5; -.
DR   PDBsum; 4RGW; -.
DR   PDBsum; 4YYM; -.
DR   PDBsum; 4YYN; -.
DR   PDBsum; 5FUR; -.
DR   PDBsum; 5I1Q; -.
DR   PDBsum; 5I29; -.
DR   ProteinModelPortal; P21675; -.
DR   SMR; P21675; -.
DR   BioGrid; 112735; 72.
DR   DIP; DIP-147N; -.
DR   IntAct; P21675; 34.
DR   MINT; MINT-1211825; -.
DR   STRING; 9606.ENSP00000276072; -.
DR   BindingDB; P21675; -.
DR   ChEMBL; CHEMBL3217390; -.
DR   iPTMnet; P21675; -.
DR   PhosphoSitePlus; P21675; -.
DR   BioMuta; TAF1; -.
DR   DMDM; 115942; -.
DR   EPD; P21675; -.
DR   MaxQB; P21675; -.
DR   PaxDb; P21675; -.
DR   PeptideAtlas; P21675; -.
DR   PRIDE; P21675; -.
DR   Ensembl; ENST00000276072; ENSP00000276072; ENSG00000147133. [P21675-2]
DR   Ensembl; ENST00000373790; ENSP00000362895; ENSG00000147133. [P21675-1]
DR   Ensembl; ENST00000423759; ENSP00000406549; ENSG00000147133. [P21675-12]
DR   GeneID; 6872; -.
DR   KEGG; hsa:6872; -.
DR   UCSC; uc004dzt.6; human. [P21675-1]
DR   CTD; 6872; -.
DR   DisGeNET; 6872; -.
DR   GeneCards; TAF1; -.
DR   GeneReviews; TAF1; -.
DR   HGNC; HGNC:11535; TAF1.
DR   HPA; CAB016283; -.
DR   HPA; HPA001075; -.
DR   MalaCards; TAF1; -.
DR   MIM; 300966; phenotype.
DR   MIM; 313650; gene.
DR   MIM; 314250; phenotype.
DR   neXtProt; NX_P21675; -.
DR   OpenTargets; ENSG00000147133; -.
DR   Orphanet; 53351; X-linked dystonia-parkinsonism.
DR   PharmGKB; PA36310; -.
DR   eggNOG; KOG0008; Eukaryota.
DR   eggNOG; COG5076; LUCA.
DR   eggNOG; COG5179; LUCA.
DR   GeneTree; ENSGT00390000012659; -.
DR   HOGENOM; HOG000020066; -.
DR   HOVERGEN; HBG050223; -.
DR   InParanoid; P21675; -.
DR   KO; K03125; -.
DR   OMA; FYYPKQQ; -.
DR   OrthoDB; EOG091G00MO; -.
DR   PhylomeDB; P21675; -.
DR   TreeFam; TF313573; -.
DR   Reactome; R-HSA-167161; HIV Transcription Initiation.
DR   Reactome; R-HSA-167162; RNA Polymerase II HIV Promoter Escape.
DR   Reactome; R-HSA-167172; Transcription of the HIV genome.
DR   Reactome; R-HSA-674695; RNA Polymerase II Pre-transcription Events.
DR   Reactome; R-HSA-6804756; Regulation of TP53 Activity through Phosphorylation.
DR   Reactome; R-HSA-73776; RNA Polymerase II Promoter Escape.
DR   Reactome; R-HSA-73779; RNA Polymerase II Transcription Pre-Initiation And Promoter Opening.
DR   Reactome; R-HSA-75953; RNA Polymerase II Transcription Initiation.
DR   Reactome; R-HSA-76042; RNA Polymerase II Transcription Initiation And Promoter Clearance.
DR   SIGNOR; P21675; -.
DR   EvolutionaryTrace; P21675; -.
DR   GeneWiki; TAF1; -.
DR   GenomeRNAi; 6872; -.
DR   PRO; PR:P21675; -.
DR   Proteomes; UP000005640; Chromosome X.
DR   Bgee; ENSG00000147133; -.
DR   ExpressionAtlas; P21675; baseline and differential.
DR   Genevisible; P21675; HS.
DR   GO; GO:0071339; C:MLL1 complex; IDA:UniProtKB.
DR   GO; GO:0000790; C:nuclear chromatin; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0005667; C:transcription factor complex; IPI:ParkinsonsUK-UCL.
DR   GO; GO:0005669; C:transcription factor TFIID complex; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0004402; F:histone acetyltransferase activity; IDA:UniProtKB.
DR   GO; GO:0016301; F:kinase activity; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0070577; F:lysine-acetylated histone binding; IDA:BHF-UCL.
DR   GO; GO:0002039; F:p53 binding; IPI:BHF-UCL.
DR   GO; GO:0046982; F:protein heterodimerization activity; IPI:ParkinsonsUK-UCL.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB.
DR   GO; GO:0000979; F:RNA polymerase II core promoter sequence-specific DNA binding; IPI:ParkinsonsUK-UCL.
DR   GO; GO:0001129; F:RNA polymerase II transcription factor activity, TBP-class protein binding, involved in preinitiation complex assembly; IBA:GO_Central.
DR   GO; GO:0043565; F:sequence-specific DNA binding; ISS:BHF-UCL.
DR   GO; GO:0017025; F:TBP-class protein binding; IPI:BHF-UCL.
DR   GO; GO:0003713; F:transcription coactivator activity; IDA:BHF-UCL.
DR   GO; GO:0008134; F:transcription factor binding; IPI:BHF-UCL.
DR   GO; GO:0061631; F:ubiquitin conjugating enzyme activity; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0007049; P:cell cycle; IEA:UniProtKB-KW.
DR   GO; GO:0071318; P:cellular response to ATP; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0006974; P:cellular response to DNA damage stimulus; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0034644; P:cellular response to UV; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0006352; P:DNA-templated transcription, initiation; ISS:BHF-UCL.
DR   GO; GO:0030901; P:midbrain development; IGI:ParkinsonsUK-UCL.
DR   GO; GO:0010629; P:negative regulation of gene expression; IMP:ParkinsonsUK-UCL.
DR   GO; GO:1905524; P:negative regulation of protein autoubiquitination; IDA:ParkinsonsUK-UCL.
DR   GO; GO:2000059; P:negative regulation of protein ubiquitination involved in ubiquitin-dependent protein catabolic process; IMP:ParkinsonsUK-UCL.
DR   GO; GO:1903026; P:negative regulation of RNA polymerase II regulatory region sequence-specific DNA binding; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0018105; P:peptidyl-serine phosphorylation; IDA:BHF-UCL.
DR   GO; GO:0018107; P:peptidyl-threonine phosphorylation; IDA:BHF-UCL.
DR   GO; GO:2000825; P:positive regulation of androgen receptor activity; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0008284; P:positive regulation of cell proliferation; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0032436; P:positive regulation of proteasomal ubiquitin-dependent protein catabolic process; IDA:BHF-UCL.
DR   GO; GO:0032092; P:positive regulation of protein binding; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0045943; P:positive regulation of transcription from RNA polymerase I promoter; IGI:ParkinsonsUK-UCL.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; IDA:BHF-UCL.
DR   GO; GO:0060261; P:positive regulation of transcription initiation from RNA polymerase II promoter; ISS:BHF-UCL.
DR   GO; GO:0046777; P:protein autophosphorylation; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0000209; P:protein polyubiquitination; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0050821; P:protein stabilization; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0042787; P:protein ubiquitination involved in ubiquitin-dependent protein catabolic process; IDA:ParkinsonsUK-UCL.
DR   GO; GO:1902806; P:regulation of cell cycle G1/S phase transition; TAS:ParkinsonsUK-UCL.
DR   GO; GO:1901796; P:regulation of signal transduction by p53 class mediator; TAS:Reactome.
DR   GO; GO:0010767; P:regulation of transcription from RNA polymerase II promoter in response to UV-induced DNA damage; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0060260; P:regulation of transcription initiation from RNA polymerase II promoter; NAS:ParkinsonsUK-UCL.
DR   GO; GO:0051123; P:RNA polymerase II transcriptional preinitiation complex assembly; ISS:BHF-UCL.
DR   GO; GO:0006368; P:transcription elongation from RNA polymerase II promoter; TAS:Reactome.
DR   GO; GO:0036369; P:transcription factor catabolic process; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0006366; P:transcription from RNA polymerase II promoter; TAS:Reactome.
DR   GO; GO:0006367; P:transcription initiation from RNA polymerase II promoter; TAS:Reactome.
DR   GO; GO:0016032; P:viral process; IEA:UniProtKB-KW.
DR   Gene3D; 1.10.1100.10; -; 1.
DR   Gene3D; 1.20.920.10; -; 2.
DR   InterPro; IPR001487; Bromodomain.
DR   InterPro; IPR018359; Bromodomain_CS.
DR   InterPro; IPR011177; TAF1_animal.
DR   InterPro; IPR009067; TAF_II_230-bd.
DR   InterPro; IPR022591; TFIID_sub1_DUF3591.
DR   Pfam; PF00439; Bromodomain; 2.
DR   Pfam; PF12157; DUF3591; 1.
DR   Pfam; PF09247; TBP-binding; 1.
DR   PIRSF; PIRSF003047; TAF1_animal; 1.
DR   PRINTS; PR00503; BROMODOMAIN.
DR   SMART; SM00297; BROMO; 2.
DR   SUPFAM; SSF47055; SSF47055; 1.
DR   SUPFAM; SSF47370; SSF47370; 2.
DR   PROSITE; PS00633; BROMODOMAIN_1; 2.
DR   PROSITE; PS50014; BROMODOMAIN_2; 2.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Acyltransferase; Alternative splicing;
KW   ATP-binding; Bromodomain; Cell cycle; Complete proteome;
KW   Disease mutation; DNA-binding; Dystonia; Host-virus interaction;
KW   Kinase; Mental retardation; Nucleotide-binding; Nucleus; Parkinsonism;
KW   Phosphoprotein; Polymorphism; Reference proteome; Repeat;
KW   Serine/threonine-protein kinase; Transcription;
KW   Transcription regulation; Transferase.
FT   CHAIN         1   1872       Transcription initiation factor TFIID
FT                                subunit 1.
FT                                /FTId=PRO_0000211215.
FT   DOMAIN        1    414       Protein kinase 1.
FT   DOMAIN     1397   1467       Bromo 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00035}.
FT   DOMAIN     1425   1872       Protein kinase 2.
FT   DOMAIN     1520   1590       Bromo 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00035}.
FT   DNA_BIND   1195   1273       HMG box.
FT   REGION      517    976       Histone acetyltransferase (HAT).
FT   REGION     1342   1629       Interaction with ASF1A and ASF1B.
FT                                {ECO:0000269|PubMed:12842904}.
FT   MOTIF      1351   1358       Nuclear localization signal.
FT                                {ECO:0000255}.
FT   COMPBIAS    157    165       Pro-rich.
FT   COMPBIAS   1627   1872       Asp/Glu-rich (acidic tail).
FT   MOD_RES     137    137       Phosphoserine; by autocatalysis.
FT                                {ECO:0000269|PubMed:8625415}.
FT   MOD_RES     307    307       Phosphoserine; by autocatalysis.
FT                                {ECO:0000244|PubMed:24275569,
FT                                ECO:0000269|PubMed:8625415}.
FT   MOD_RES     544    544       N6-acetyllysine.
FT                                {ECO:0000250|UniProtKB:Q80UV9}.
FT   MOD_RES    1669   1669       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q80UV9}.
FT   MOD_RES    1672   1672       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q80UV9}.
FT   MOD_RES    1778   1778       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q80UV9}.
FT   MOD_RES    1781   1781       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q80UV9}.
FT   MOD_RES    1799   1799       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q80UV9}.
FT   MOD_RES    1826   1826       Phosphoserine.
FT                                {ECO:0000244|PubMed:19690332}.
FT   VAR_SEQ     177    177       G -> GVSENGEGIILPSIIAPSSLAS (in isoform 2
FT                                and isoform N-TAF1).
FT                                {ECO:0000303|PubMed:17273961}.
FT                                /FTId=VSP_012362.
FT   VAR_SEQ    1525   1540       SWPFHHPVNKKFVPDY -> VSCLCAKYFLAISSPS (in
FT                                isoform 2i).
FT                                {ECO:0000303|PubMed:17952504}.
FT                                /FTId=VSP_053376.
FT   VAR_SEQ    1525   1528       SWPF -> IITK (in isoform 2h).
FT                                {ECO:0000303|PubMed:17952504}.
FT                                /FTId=VSP_053375.
FT   VAR_SEQ    1529   1872       Missing (in isoform 2h).
FT                                {ECO:0000303|PubMed:17952504}.
FT                                /FTId=VSP_053377.
FT   VAR_SEQ    1541   1872       Missing (in isoform 2i).
FT                                {ECO:0000303|PubMed:17952504}.
FT                                /FTId=VSP_053378.
FT   VAR_SEQ    1585   1592       PESQYTKT -> YMCTTCRT (in isoform 2e).
FT                                {ECO:0000303|PubMed:12928496,
FT                                ECO:0000303|PubMed:17952504}.
FT                                /FTId=VSP_053379.
FT   VAR_SEQ    1593   1872       Missing (in isoform 2e).
FT                                {ECO:0000303|PubMed:12928496,
FT                                ECO:0000303|PubMed:17952504}.
FT                                /FTId=VSP_053380.
FT   VAR_SEQ    1645   1645       Q -> QAK (in isoform 2d, isoform 2g and
FT                                isoform N-TAF1).
FT                                {ECO:0000303|PubMed:12928496,
FT                                ECO:0000303|PubMed:17273961,
FT                                ECO:0000303|PubMed:17952504}.
FT                                /FTId=VSP_053381.
FT   VAR_SEQ    1684   1686       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:12928496}.
FT                                /FTId=VSP_053382.
FT   VAR_SEQ    1687   1687       Q -> QMRQGRGRLGEEDSDVDIEGYDDEEEDGKPKTPAP
FT                                (in isoform 2g, isoform 2a, isoform 3 and
FT                                isoform 4). {ECO:0000303|PubMed:12928496,
FT                                ECO:0000303|PubMed:17952504,
FT                                ECO:0000303|Ref.7}.
FT                                /FTId=VSP_053383.
FT   VAR_SEQ    1799   1872       SYGSYEEPDPKSNTQDTSFSSIGGYEVSEEEEDEEEEEQRS
FT                                GPSVLSQVHLSEDEEDSEDFHSIAGDSDLDSDE -> RYQ
FT                                (in isoform 2g, isoform 2a, isoform 2c,
FT                                isoform 2d and isoform 3).
FT                                {ECO:0000303|PubMed:12928496,
FT                                ECO:0000303|PubMed:17952504}.
FT                                /FTId=VSP_053384.
FT   VARIANT     269    269       L -> V (in dbSNP:rs28382158).
FT                                {ECO:0000269|PubMed:17344846,
FT                                ECO:0000269|Ref.5}.
FT                                /FTId=VAR_020678.
FT   VARIANT     297    297       A -> G (in dbSNP:rs35317750).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041930.
FT   VARIANT     453    453       G -> D (in a colorectal adenocarcinoma
FT                                sample; somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041931.
FT   VARIANT     472    472       N -> D (found in a patient with X-linked
FT                                intellectual disability; unknown
FT                                pathological significance;
FT                                dbSNP:rs200177996).
FT                                {ECO:0000269|PubMed:25644381}.
FT                                /FTId=VAR_077838.
FT   VARIANT     575    575       P -> S (in MRXS33; dbSNP:rs864321630).
FT                                {ECO:0000269|PubMed:26637982}.
FT                                /FTId=VAR_076394.
FT   VARIANT     651    651       E -> K (in a metastatic melanoma sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041932.
FT   VARIANT     691    691       M -> I (in a lung bronchoalveolar
FT                                carcinoma sample; somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041933.
FT   VARIANT     786    786       C -> R (in MRXS33; dbSNP:rs864321628).
FT                                {ECO:0000269|PubMed:26637982}.
FT                                /FTId=VAR_076395.
FT   VARIANT     955    955       D -> H (in MRXS33; dbSNP:rs864321631).
FT                                {ECO:0000269|PubMed:26637982}.
FT                                /FTId=VAR_076396.
FT   VARIANT    1169   1169       R -> C (found in a patient with X-linked
FT                                intellectual disability; unknown
FT                                pathological significance).
FT                                {ECO:0000269|PubMed:25644381}.
FT                                /FTId=VAR_077839.
FT   VARIANT    1225   1225       R -> W (in MRXS33; dbSNP:rs864321629).
FT                                {ECO:0000269|PubMed:26637982}.
FT                                /FTId=VAR_076397.
FT   VARIANT    1316   1316       I -> T (in MRXS33; dbSNP:rs864321627).
FT                                {ECO:0000269|PubMed:26637982}.
FT                                /FTId=VAR_076398.
FT   VARIANT    1383   1383       V -> I (in dbSNP:rs7050748).
FT                                /FTId=VAR_048433.
FT   VARIANT    1431   1431       R -> H (in MRXS33; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:26637982}.
FT                                /FTId=VAR_076399.
FT   VARIANT    1496   1496       N -> H (in MRXS33; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:26637982}.
FT                                /FTId=VAR_076400.
FT   MUTAGEN     137    137       S->A: No decrease in kinase activity.
FT                                {ECO:0000269|PubMed:9660973}.
FT   MUTAGEN     145    145       D->A: Reduces kinase activity; when
FT                                associated with A-147; A-149; A-150; A-
FT                                152 and A-154.
FT                                {ECO:0000269|PubMed:9660973}.
FT   MUTAGEN     147    147       D->A: Reduces kinase activity; when
FT                                associated with A-145; A-149; A-150; A-
FT                                152 and A-154.
FT                                {ECO:0000269|PubMed:9660973}.
FT   MUTAGEN     149    149       E->A: Reduces kinase activity; when
FT                                associated with A-145; A-147; A-150; A-
FT                                152 and A-154.
FT                                {ECO:0000269|PubMed:9660973}.
FT   MUTAGEN     150    150       D->A: Reduces kinase activity; when
FT                                associated with A-145; A-147; A-149; A-
FT                                152 and A-154.
FT                                {ECO:0000269|PubMed:9660973}.
FT   MUTAGEN     152    152       D->A: Reduces kinase activity; when
FT                                associated with A-145; A-147; A-149; A-
FT                                150 and A-154.
FT                                {ECO:0000269|PubMed:9660973}.
FT   MUTAGEN     154    154       K->A: Reduces kinase activity; when
FT                                associated with A-145; A-147; A-149; A-
FT                                150 and A-152.
FT                                {ECO:0000269|PubMed:9660973}.
FT   MUTAGEN     305    305       C->A: Reduces kinase activity; when
FT                                associated with A-307; A-308; A-309 and
FT                                A-310. {ECO:0000269|PubMed:9660973}.
FT   MUTAGEN     307    307       S->A: Reduces kinase activity; when
FT                                associated with A-305; A-308; A-309 and
FT                                A-310. {ECO:0000269|PubMed:9660973}.
FT   MUTAGEN     308    308       D->A: Reduces kinase activity; when
FT                                associated with A-305; A-307; A-309 and
FT                                A-310. {ECO:0000269|PubMed:9660973}.
FT   MUTAGEN     309    309       D->A: Reduces kinase activity; when
FT                                associated with A-305; A-307; A-308 and
FT                                A-310. {ECO:0000269|PubMed:9660973}.
FT   MUTAGEN     310    310       E->A: Reduces kinase activity; when
FT                                associated with A-305; A-307; A-308 and
FT                                A-309. {ECO:0000269|PubMed:9660973}.
FT   MUTAGEN     721    721       E->Q: 25% decrease in histone
FT                                acetylation.
FT                                {ECO:0000269|PubMed:15870300}.
FT   MUTAGEN     827    829       Missing: Dramatic decrease in histone
FT                                acetylation.
FT                                {ECO:0000269|PubMed:15870300}.
FT   HELIX       593    596       {ECO:0000244|PDB:4RGW}.
FT   TURN        600    602       {ECO:0000244|PDB:4RGW}.
FT   HELIX       609    613       {ECO:0000244|PDB:4RGW}.
FT   TURN        614    616       {ECO:0000244|PDB:4RGW}.
FT   STRAND      624    626       {ECO:0000244|PDB:4RGW}.
FT   HELIX       627    629       {ECO:0000244|PDB:4RGW}.
FT   STRAND      630    632       {ECO:0000244|PDB:4RGW}.
FT   STRAND      634    638       {ECO:0000244|PDB:4RGW}.
FT   HELIX       640    655       {ECO:0000244|PDB:4RGW}.
FT   TURN        656    658       {ECO:0000244|PDB:4RGW}.
FT   HELIX       668    671       {ECO:0000244|PDB:4RGW}.
FT   STRAND      675    685       {ECO:0000244|PDB:4RGW}.
FT   STRAND      697    704       {ECO:0000244|PDB:4RGW}.
FT   STRAND      708    710       {ECO:0000244|PDB:4RGW}.
FT   STRAND      718    724       {ECO:0000244|PDB:4RGW}.
FT   STRAND      729    732       {ECO:0000244|PDB:4RGW}.
FT   STRAND      739    756       {ECO:0000244|PDB:4RGW}.
FT   STRAND      761    767       {ECO:0000244|PDB:4RGW}.
FT   STRAND      770    774       {ECO:0000244|PDB:4RGW}.
FT   STRAND      778    782       {ECO:0000244|PDB:4RGW}.
FT   HELIX       797    817       {ECO:0000244|PDB:4RGW}.
FT   STRAND      820    822       {ECO:0000244|PDB:4RGW}.
FT   STRAND      824    826       {ECO:0000244|PDB:4RGW}.
FT   HELIX       827    833       {ECO:0000244|PDB:4RGW}.
FT   HELIX       839    847       {ECO:0000244|PDB:4RGW}.
FT   STRAND      850    853       {ECO:0000244|PDB:4RGW}.
FT   STRAND      856    858       {ECO:0000244|PDB:4RGW}.
FT   STRAND      861    864       {ECO:0000244|PDB:4RGW}.
FT   HELIX       873    879       {ECO:0000244|PDB:4RGW}.
FT   HELIX       882    900       {ECO:0000244|PDB:4RGW}.
FT   HELIX       905    907       {ECO:0000244|PDB:4RGW}.
FT   HELIX       925    928       {ECO:0000244|PDB:4RGW}.
FT   HELIX       931    942       {ECO:0000244|PDB:4RGW}.
FT   STRAND      947    952       {ECO:0000244|PDB:4RGW}.
FT   STRAND      958    962       {ECO:0000244|PDB:4RGW}.
FT   STRAND      964    968       {ECO:0000244|PDB:4RGW}.
FT   HELIX      1055   1078       {ECO:0000244|PDB:4RGW}.
FT   HELIX      1381   1397       {ECO:0000244|PDB:3UV5}.
FT   HELIX      1403   1405       {ECO:0000244|PDB:3UV5}.
FT   STRAND     1406   1408       {ECO:0000244|PDB:3AAD}.
FT   TURN       1411   1413       {ECO:0000244|PDB:3UV5}.
FT   HELIX      1417   1420       {ECO:0000244|PDB:3UV5}.
FT   HELIX      1427   1435       {ECO:0000244|PDB:3UV5}.
FT   HELIX      1442   1460       {ECO:0000244|PDB:3UV5}.
FT   STRAND     1462   1464       {ECO:0000244|PDB:3AAD}.
FT   HELIX      1465   1483       {ECO:0000244|PDB:3UV5}.
FT   HELIX      1485   1495       {ECO:0000244|PDB:3UV5}.
FT   TURN       1497   1500       {ECO:0000244|PDB:3UV5}.
FT   HELIX      1502   1517       {ECO:0000244|PDB:5I29}.
FT   TURN       1518   1521       {ECO:0000244|PDB:5I29}.
FT   HELIX      1526   1528       {ECO:0000244|PDB:5I29}.
FT   TURN       1534   1536       {ECO:0000244|PDB:5I29}.
FT   HELIX      1540   1543       {ECO:0000244|PDB:5I29}.
FT   HELIX      1550   1558       {ECO:0000244|PDB:5I29}.
FT   HELIX      1565   1583       {ECO:0000244|PDB:5I29}.
FT   HELIX      1588   1606       {ECO:0000244|PDB:5I29}.
FT   HELIX      1608   1634       {ECO:0000244|PDB:5I29}.
SQ   SEQUENCE   1872 AA;  212677 MW;  93BE3D181A72ABEB CRC64;
     MGPGCDLLLR TAATITAAAI MSDTDSDEDS AGGGPFSLAG FLFGNINGAG QLEGESVLDD
     ECKKHLAGLG ALGLGSLITE LTANEELTGT DGALVNDEGW VRSTEDAVDY SDINEVAEDE
     SRRYQQTMGS LQPLCHSDYD EDDYDADCED IDCKLMPPPP PPPGPMKKDK DQDSITGEKV
     DFSSSSDSES EMGPQEATQA ESEDGKLTLP LAGIMQHDAT KLLPSVTELF PEFRPGKVLR
     FLRLFGPGKN VPSVWRSARR KRKKKHRELI QEEQIQEVEC SVESEVSQKS LWNYDYAPPP
     PPEQCLSDDE ITMMAPVESK FSQSTGDIDK VTDTKPRVAE WRYGPARLWY DMLGVPEDGS
     GFDYGFKLRK TEHEPVIKSR MIEEFRKLEE NNGTDLLADE NFLMVTQLHW EDDIIWDGED
     VKHKGTKPQR ASLAGWLPSS MTRNAMAYNV QQGFAATLDD DKPWYSIFPI DNEDLVYGRW
     EDNIIWDAQA MPRLLEPPVL TLDPNDENLI LEIPDEKEEA TSNSPSKESK KESSLKKSRI
     LLGKTGVIKE EPQQNMSQPE VKDPWNLSND EYYYPKQQGL RGTFGGNIIQ HSIPAVELRQ
     PFFPTHMGPI KLRQFHRPPL KKYSFGALSQ PGPHSVQPLL KHIKKKAKMR EQERQASGGG
     EMFFMRTPQD LTGKDGDLIL AEYSEENGPL MMQVGMATKI KNYYKRKPGK DPGAPDCKYG
     ETVYCHTSPF LGSLHPGQLL QAFENNLFRA PIYLHKMPET DFLIIRTRQG YYIRELVDIF
     VVGQQCPLFE VPGPNSKRAN THIRDFLQVF IYRLFWKSKD RPRRIRMEDI KKAFPSHSES
     SIRKRLKLCA DFKRTGMDSN WWVLKSDFRL PTEEEIRAMV SPEQCCAYYS MIAAEQRLKD
     AGYGEKSFFA PEEENEEDFQ MKIDDEVRTA PWNTTRAFIA AMKGKCLLEV TGVADPTGCG
     EGFSYVKIPN KPTQQKDDKE PQPVKKTVTG TDADLRRLSL KNAKQLLRKF GVPEEEIKKL
     SRWEVIDVVR TMSTEQARSG EGPMSKFARG SRFSVAEHQE RYKEECQRIF DLQNKVLSST
     EVLSTDTDSS SAEDSDFEEM GKNIENMLQN KKTSSQLSRE REEQERKELQ RMLLAAGSAA
     SGNNHRDDDT ASVTSLNSSA TGRCLKIYRT FRDEEGKEYV RCETVRKPAV IDAYVRIRTT
     KDEEFIRKFA LFDEQHREEM RKERRRIQEQ LRRLKRNQEK EKLKGPPEKK PKKMKERPDL
     KLKCGACGAI GHMRTNKFCP LYYQTNAPPS NPVAMTEEQE EELEKTVIHN DNEELIKVEG
     TKIVLGKQLI ESADEVRRKS LVLKFPKQQL PPKKKRRVGT TVHCDYLNRP HKSIHRRRTD
     PMVTLSSILE SIINDMRDLP NTYPFHTPVN AKVVKDYYKI ITRPMDLQTL RENVRKRLYP
     SREEFREHLE LIVKNSATYN GPKHSLTQIS QSMLDLCDEK LKEKEDKLAR LEKAINPLLD
     DDDQVAFSFI LDNIVTQKMM AVPDSWPFHH PVNKKFVPDY YKVIVNPMDL ETIRKNISKH
     KYQSRESFLD DVNLILANSV KYNGPESQYT KTAQEIVNVC YQTLTEYDEH LTQLEKDICT
     AKEAALEEAE LESLDPMTPG PYTPQPPDLY DTNTSLSMSR DASVFQDESN MSVLDIPSAT
     PEKQVTQEGE DGDGDLADEE EGTVQQPQAS VLYEDLLMSE GEDDEEDAGS DEEGDNPFSA
     IQLSESGSDS DVGSGGIRPK QPRMLQENTR MDMENEESMM SYEGDGGEAS HGLEDSNISY
     GSYEEPDPKS NTQDTSFSSI GGYEVSEEEE DEEEEEQRSG PSVLSQVHLS EDEEDSEDFH
     SIAGDSDLDS DE
//
